BiotechTube
Allogene Therapeutics

Allogene Therapeutics

ALLO
United States

Allogene Therapeutics is dedicated to creating and leading the next revolution in cell therapy by delivering the first allogeneic CAR T cell products. The company leverages its proprietary AlloCAR T platform, featuring multiplex gene-engineering, gene-editing, and a proprietary lymphodepletion regimen, to develop scalable, on-demand treatments. With a pipeline targeting blood cancers, solid tumors like renal cell carcinoma, and autoimmune diseases, Allogene is advancing multiple clinical programs, including the industry's first pivotal Phase 2 trial for a frontline allogeneic CAR T in lymphoma. The company is publicly traded and led by a team with deep CAR T expertise.

allogene.com

ALLO · Stock Price

USD 2.21+0.64 (+40.76%)
Market Cap: $571.7M

Historical price data

AI Company Overview

Allogene Therapeutics is dedicated to creating and leading the next revolution in cell therapy by delivering the first allogeneic CAR T cell products. The company leverages its proprietary AlloCAR T platform, featuring multiplex gene-engineering, gene-editing, and a proprietary lymphodepletion regimen, to develop scalable, on-demand treatments. With a pipeline targeting blood cancers, solid tumors like renal cell carcinoma, and autoimmune diseases, Allogene is advancing multiple clinical programs, including the industry's first pivotal Phase 2 trial for a frontline allogeneic CAR T in lymphoma. The company is publicly traded and led by a team with deep CAR T expertise.

OncologyAutoimmune Diseases

Technology Platform

The AlloCAR T™ platform utilizes gene-editing (e.g., TALEN®) to create 'off-the-shelf' CAR T cell therapies from healthy donor cells, combined with a proprietary lymphodepletion regimen (ALLO-647) to enable patient readiness and scalable manufacturing.

Pipeline

8
8 drugs in pipeline
DrugIndicationStageWatch
Fludarabine + CyclophosphamideLarge B-cell LymphomaPhase 2
ALLO-647 + Fludarabine + CyclophosphamideRelapsed/Refractory Large B Cell LymphomaPhase 2
ALLO-647 + Fludarabine + CyclophosphamideRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaPhase 1/2
ALLO-647 + Fludarabine + CyclophosphamideRelapsed/Refractory Multiple MyelomaPhase 1/2
ALLO-647 + Fludarabine + CyclophosphamideAdvanced/Metastatic Clear Cell Renal Cell CarcinomaPhase 1

Funding History

3
Total raised:$793.6M
PIPE$120MAug 15, 2020
IPO$373.6MOct 11, 2018
Series A$300MApr 15, 2018

Opportunities

The primary opportunity is to establish 'off-the-shelf' CAR T as the new standard in frontline lymphoma, a significantly larger market than relapsed/refractory settings.
Additional major opportunities include penetrating the vast solid tumor market (starting with RCC) and pioneering the use of CAR T in autoimmune diseases, both enabled by the scalability and repeat-dosing potential of the allogeneic platform.

Risk Factors

Key risks include clinical failure in pivotal trials, particularly around durability and safety compared to autologous CAR T; regulatory hurdles for a novel modality; host immune rejection limiting product persistence; and intense competition from both improved autologous therapies and other allogeneic platforms.

Competitive Landscape

Allogene competes with other allogeneic CAR T developers (e.g., CRISPR Therapeutics, Precision BioSciences) and must demonstrate superiority or equivalence to entrenched autologous CAR T products from Gilead/Kite and Bristol Myers Squibb. Its differentiation lies in its integrated platform, advanced clinical stage, and leadership team with direct autologous CAR T commercialization experience.